Akebia Therapeutics
AKBA
Akebia Therapeutics (AKBA) news
Recent news
Akebia Therapeutics - Initial data from phase 2 Ebribafusp trial expected in 2027
AInvest Wire · Sep 14, 2026Akebia Therapeutics announces first patient dosed in phase 2 basket trial of ebribafusp in rare complement-mediated kidney diseases
AInvest Wire · Sep 14, 2026Akebia Therapeutics - no significant difference in mortality: VafseO 8.77% vs ESA 8.78% per 100 patient-years
Akebia Therapeutics, Inc. (Nasdaq: AKBA) has reported findings from a post-hoc win odds analysis of its drug Vafseo® (vadadustat) in the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent patients. The analysis, based on data from the Phase 3 INNO2VATE trials, compared…
AInvest Wire · Jun 30, 2026Akebia Therapeutics - voice trial meets stopping criteria with win odds of 1.16 as of June 1, 2026
AInvest Wire · Jun 30, 2026Akebia Therapeutics Q3 EPS $(0.08), inline, sales $42.05M Miss $48.18M estimate
AInvest Wire · Nov 8, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.